Stock Analysis, Dividends, Split History

LILA / Liberty Global plc LiLAC Class A financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price18.38
Volume213,100.00
Market Cap ($M)11,809.08
Enterprise Value ($M)55,691.19
Book Value ($M)11,998.50
Book Value / Share18.79
Price / Book0.98
NCAV ($M)-64,083.60
NCAV / Share-100.34
Price / NCAV-0.18
Share Statistics
Common Shares Outstanding6 252,805,601
Common Shares Outstanding2 30,773,233
Common Shares Outstanding4 10,472,517
Common Shares Outstanding 523,423
Common Shares Outstanding5 581,034,556
Common Shares Outstanding3 12,630,744
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.07
Balance Sheet (mrq) ($M)
Assets80,973.50
Liabilities68,008.20
Quick Ration/a
Current Ratio0.45
Income Statement (mra) ($M)
Revenues18,280,000,000.00
Operating Income2,349.20
Net Income-1,049.50
Cash Flow Statement (mra) ($M)
Cash From Operations5,705.80
Cash from Investing-3,829.40
Cash from Financing-3,829.40
Identifiers and Descriptors
CUSIPG5480U138
Central Index Key (CIK)1570585

Split History

Stock splits are used by Liberty Global plc LiLAC Class A to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Tracking Glenn Greenberg's Brave Warrior Advisors Portfolio - Q2 2018 Update

2h seekingalpha
The largest three positions are Alliance Data Systems, Alphabet, and Charles Schwab, and they add up to ~43% of the portfolio. (76-0)

Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q2 2018 Update

21h seekingalpha
Berkshire Hathaway increased US Bancorp, Goldman Sachs, Southwest Airlines, and Delta Airlines while reducing Phillips 66. (153-3)

UPDATE 1-Berkshire boosts Goldman, Teva stakes; buys more Apple

2018-08-15 reuters
(Reuters) - Warren Buffett’s Berkshire Hathaway Inc (BRKa.N) boosted its investments in Goldman Sachs Group Inc (GS.N) and Israel’s Teva Pharmaceutical Industries Ltd (TEVA.TA) during the second quarter and confirmed it has expanded its already huge bet on iPhone maker Apple Inc (AAPL.O). (61-1)

Big Changes To Berkshire's Portfolio In Q2 – ValueWalk Premium

2018-08-14 valuewalkpremium
In an SEC 13F filing after the market closed today, Berkshire Hathaway revealed major changes to its portfolio as of June 30, 2018. (15-0)

Tracking Allan Mecham's Arlington Value Capital Portfolio - Q2 2018 Update

2018-08-14 seekingalpha
Arlington Value Capital’s 13F portfolio value increased from $1.21B to $1.28B. The number of positions remained steady at 20. (54-0)

CUSIP: G5480U138